IKZF3

Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple Myeloma

Mezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.